Referrals to the Genentech Patient Foundation
The Genentech® Access to Care Foundation is now the Genentech Patient Foundation.
We are still focused on giving free medicines to patients in need, but we've made some changes to provide better support to more patients, more quickly.
The Genentech Patient Foundation provides free medicines to people:
- Who don't have insurance
- Whose treatment is not covered by insurance
- Who are struggling with high out-of-pocket costs
To learn more and to apply for help, visit GenentechPatientFoundation.com.
To be eligible for free Genentech medicine from the Genentech
Patient Foundation, insured patients who have coverage for their
medicine must have exhausted all other forms of patient assistance
(including the HEMLIBRA Co-pay Program and support from independent
co-pay assistance foundations) and must meet financial criteria.
Uninsured patients and insured patients without coverage for their
medicine must meet different financial criteria.
Download this flash card to learn more about the Genentech Patient Foundation.
PAN=Patient Authorization and Notice of Request
for Transmission of Health Information to Genentech Access Solutions
and Genentech® Access to Care Foundation.
SMN=Statement of Medical Necessity.
Important Safety Information & Indication
HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A with or without factor VIII inhibitors.
Important Safety Information
Boxed WARNING: THROMBOTIC MICROANGIOPATHY and THROMBOEMBOLISM
Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.
Warnings and Precautions
- Laboratory coagulation test interference: HEMLIBRA interferes with activated clotting time (ACT); activated partial thromboplastin time (aPTT); and coagulation laboratory tests based on aPTT, including one-stage, aPTT-based single-factor assays; aPTT-based Activated Protein C Resistance (APC-R); and Bethesda assays (clotting-based) for factor VIII (FVIII) inhibitor titers. Intrinsic pathway clotting-based laboratory tests should not be used
Most Common Adverse Reactions
The most common adverse reactions (incidence ≥10%) are injection site reactions, headache, and arthralgia.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see the HEMLIBRA full Prescribing Information for additional Important Safety Information, including Boxed WARNING.